Robert Pilarski, MS, LGC, MSW, LSW, presented “Current Prostate Cancer Genetic Testing Capabilities and Considerations” for the Grand Rounds in Urology audience in January 2020.
How to cite: Pilarski, Robert. “Current Prostate Cancer Genetic Testing Capabilities and Considerations” December, 2020. Accessed Jul 2024. https://grandroundsinurology.com/current-prostate-cancer-genetic-testing-capabilities-and-considerations/
Current Prostate Cancer Genetic Testing Capabilities and Considerations – Summary:
Robert Pilarski, MS, LGC, MSW, LSW, a certified genetic counselor, reviews the range of options currently available for genetic screening for prostate cancer. He weighs the advantages and disadvantages of different options for genetic testing, suggests criteria for selecting a lab, and discusses controversies with direct-to-consumer genetic testing.
This educational activity is based on a series of lectures on genetic testing for prostate cancer from the 2019 Philadelphia Prostate Cancer Consensus Conference. Further activities from this conference include:
Germline Predisposition for Prostate Cancer Among African American and Other Minorities: What Do We Know?
Molecular Insights into the Germline for Prostate Cancer Initiation, Progression, and Aggressiveness
Prostate Cancer Screening & Genetic Testing: The NCCN Perspective
A Urologist’s Perspective on Germline Testing
Integration of Germline Testing in Prostate Cancer Screening
Current NCCN Recommendations for Prostate Cancer Genetic Testing
The Expanding World of Germline Testing for Prostate Cancer: Genetic Counseling Perspective
The Expanding World of Germline Testing for Prostate Cancer: A Clinical Trials Perspective
ABOUT THE AUTHOR
Robert Pilarski is a licensed and board-certified genetic counselor and Professor of Clinical Internal Medicine at the Wexner Medical Center and James Comprehensive Cancer Center at Ohio State University. Mr. Pilarski’s clinical responsibilities include counseling patients and families with a variety of cancer syndromes about cancer risks, genetic testing, and medical management. In addition, he researches clinical aspects of Cowden syndrome and the PTEN Hamartoma Tumor syndrome (PHTS), and he is the study coordinator and co-investigator for the OSU Breast Cancer Tissue Bank and a study on the genetics of uveal melanoma which helped identify BAP1 as a tumor predisposition gene. He has over 80 publications in medical and scientific journals. He has presented regularly at national and regional conferences, and has served as an ad hoc reviewer for numerous medical and genetics journals. Mr. Pilarski is a past board member of the National Society of Genetic Counselors, and Co-Founder and past-President of its Cancer Genetics Special Interest Group. He is the Vice-Chair of the National Comprehensive Cancer Network’s guidelines panel on Genetic/Familial High-Risk Assessment: Breast and Ovarian Cancers.
